The oncology company will discuss its dual approach to RAS-targeted programs when it appears at the H.C. Wainwright conference.
Verastem Oncology is scheduled to present at the H.C. Wainwright conference, where it plans to discuss a dual-track strategy focused on RAS-targeted programs.
Further verified details about the specifics of the presentation or the company's RAS pipeline were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
